Cipla Limited has formally notified stock exchanges about an upcoming board meeting scheduled for Wednesday, May 13, 2026, to review and approve the company's financial performance for the fourth quarter and full year ended March 31, 2026. The pharmaceutical company communicated this development through official intimation to BSE Limited, National Stock Exchange of India Limited, and Societe de la Bourse de Luxembourg under Regulation 29 of SEBI Listing Regulations.

Board Meeting Agenda

The board meeting will address two primary matters of significant importance to stakeholders:

Trading Window Restrictions

In compliance with the company's Code of Conduct for Prevention of Insider Trading, Cipla has implemented a trading window closure for dealing in company securities. The restriction period extends from Wednesday, April 1, 2026, through Friday, May 15, 2026, both days inclusive.

Regulatory Compliance

The intimation was issued on March 31, 2026, and signed by Company Secretary Rajendra Chopra. This notification fulfills the company's obligations under Regulation 29 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, ensuring transparent communication with investors and regulatory bodies about material corporate developments.

The pharmaceutical major's adherence to regulatory timelines demonstrates its commitment to corporate governance standards and investor protection measures. The trading window closure serves as a preventive measure against potential insider trading activities during the sensitive period surrounding financial results announcement.

Cipla Limited has formalized its leadership transition through a Board meeting held on 30th March, 2026, following the successful completion of its postal ballot process where shareholders approved all four proposed resolutions with strong majorities. The pharmaceutical company announced the results on 26th March, 2026, after the e-voting process concluded on 25th March, 2026.

Leadership Appointments Approved Through Postal Ballot

Shareholders demonstrated strong support for the company's leadership changes, approving the appointment of Mr Achin Gupta (DIN: 09491674) in multiple capacities. The voting results showed overwhelming approval across all shareholder categories.

Senior Management Personnel Categorization

Following Mr Achin Gupta taking charge as Managing Director and Global Chief Executive Officer, the Board of Directors formally categorized two key officials as Senior Management Personnel effective 1st April, 2026. Both officials report directly to the new MD and CEO.

Mr Saurabh Gambhir brings extensive experience from leadership roles at Emcure Pharmaceuticals, Intas Pharmaceuticals, and IMS Health (now IQVIA). He holds an MBA from IIM Ahmedabad and is responsible for strategic planning, inorganic growth opportunities, and digital transformation programs. At Cipla, he leads strategic planning, inorganic growth opportunities, and digital transformation programs, contributing to strengthening the company's competitive positioning.

Mr Satyavan Manikani joined Cipla in February 2022 and has previously held leadership positions at USV Limited, Gufic Biosciences Ltd, Alkem Labs, and Ranbaxy Labs. He is a pharmacy graduate with an MBA in Marketing from the Institute of Technology & Management, Mumbai, and leads portfolio initiatives globally.

Director Resignation Formalized

Upon completion of his term as Managing Director and Global Chief Executive Officer on 31st March, 2026, Mr Umang Vohra (DIN: 02296740) has resigned as Director of the company effective 1st April, 2026. In his resignation letter dated 30th March, 2026, Vohra expressed gratitude for his ten-year tenure at Cipla and acknowledged the support of Chairman Dr Y K Hamied and the Board.

Voting Participation and Regulatory Compliance

The postal ballot process witnessed significant shareholder participation, with 650905507 votes cast representing 80.58% of the total outstanding shares of 807780677. The e-voting facility was provided by National Securities Depository Limited (NSDL).

The postal ballot process was conducted in compliance with Section 108 and Section 110 of the Companies Act, 2013, along with relevant rules and SEBI Listing Regulations. The leadership changes have been disclosed under Regulation 30 of SEBI Listing Regulations, with detailed annexures providing comprehensive information as per SEBI circular requirements. The voting process was overseen by Mr Avinash Bagul, Partner at M/s BNP & Associates, ensuring full regulatory compliance.